Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies

Oncology (Switzerland)

Volumn 86, Issue 5-6, 2014, Pages 271-278

  Hayman, Suzanne R ^a   Calle, Juan C ^a   Jatoi, Aminah ^a   Craici, Iasmina M ^b   Wagner, Steven J ^b   Weaver, Amy L ^a   Greene, Eddie L ^a   Grande, Joseph P ^a   Garovic, Vesna D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Antivascular endothelial growth factor therapy; Hypertension; Malignancy; Podocyturia; Proteinuria

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DASATINIB; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PODOCIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOID; CELL CULTURE; CELL LOSS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; CYTOTOXICITY; FEMALE; GASTROINTESTINAL CARCINOMA; GLOMERULAR DYSFUNCTION; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY CELL CULTURE; KIDNEY FUNCTION; MALE; OVARY CANCER; OVERALL SURVIVAL; PODOCYTE; PODOCYTURIA; PRIORITY JOURNAL; PROTEINURIA; UNSPECIFIED SIDE EFFECT; URINALYSIS; CANCER PATIENT; CELL COUNT; HUMAN CELL; PROTEIN URINE LEVEL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PODOCYTES; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901728046     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000360180     Document Type: Article

References (45)

1. Granger JP: Vascular endothelial growth factor inhibitors and hypertension: A central role for the kidney and endothelial factorŞ. Hypertension 2009; 54: 465-467
2. Maharaj A, D'Amore PA: Roles for VEGF in the adult. Microvasc Res 2007; 74: 100-113
3. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
4. Daniels BS: The role of the glomerular epithelial cell in the maintenance of the glomerular filtration barrier. Am J Nephrol 1993; 13: 318-323
5. Barisoni L, Mundel P: Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol 2003; 23: 353-360
6. Kennedy C: What type of VEGF do you need?. J Am Soc Nephrol 2010; 21: 1410-1412
7. Qiu Y, Ferguson J, Oltean S, et al: Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 2010; 21: 1498-1509
8. Parikh SM, Pollak MR: VEGF receptors and glomerular function. J Am Soc Nephrol 2010; 21: 1599-1600
9. Genentech: Avastin (bevacizumab) [Product insert], South San Francisco, Genentech, 2009
10. Gurevich F, Perazella MA: Renal effects of anti- Angiogenesis therapy: Update for the internist. Am J Med 2009; 122: 322-328
11. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795
12. Launay-Vacher V, Deray G: Hypertension and proteinuria: A class-effect of antiangiogenic therapies. Anticancer Drugs 2009; 20: 81-82
13. Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-Analysis. Am J Kidney Dis 2007; 49: 186-193
14. Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21: 1381-1389
15. Halimi JM, Azizi M, Bobrie G, et al: Vascular and renal effects of anti-Angiogenic therapy (in French). Nephrol Ther 2008; 4: 602-615
16. Yu D, Petermann A, Kunter U, Rong S, Shankland S, Floege J: Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741
17. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV: Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285:F40-F48
18. Nakamura T, Ushiyama C, Suzuki S, et al: Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000; 320: 112-116
19. Nakamura T, Ushiyama C, Suzuki S, et al: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15: 1379-1383
20. Hara M, Yanagihara T, Takada T, et al: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998; 18: 35-41
21. Nakamura T, Ushiyama C, Suzuki S, et al: The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000; 20: 175-179
22. Garovic VD, Wagner SJ, Turner ST, et al: Urinary podocyte excretion as a marker of preeclampsia. Am J Obstet Gynecol 2007; 196: 320.e1-e7
23. Maynard SE, Min JY, Merchan J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
24. Muller-Deile J, Brocker V, Grunwald V, et al: Renal side effects of VEGF-blocking therapy. NDT Plus 2010; 3: 172-175
25. Wilson DM, Anderson RL: Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample. Am J Clin Pathol 1993; 100: 419-424
26. Morgenstern BZ, Butani L, Wollan P, Wilson DM, Larson TS: Validity of protein-osmolality versus protein-creatinine ratios in the estimation of quantitative proteinuria from random samples of urine in children. Am J Kidney Dis 2003; 41: 760-766
27. Levey AS, Coresh J, Greene T, et al: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772
28. Petermann AT, Krofft R, Blonski M, et al: Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003; 64: 1222-1231
29. Appel D, Kershaw DB, Smeets B, et al: Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20: 333-343
30. Lasgni L, Romagnani P: Glomerular epithelial stem cells: The good, the bad, and the ugly. J Am Soc Nephrol 2010; 21: 1612-1619
31. Sato Y, Wharram BL, Lee SK, et al: Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 2009; 20: 1041-1052
32. Szeto CC, Lai KB, Chow KM, et al: Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clin Chim Acta 2005; 361: 182-190
33. Haraldsson B, Jeansson M: Glomerular filtration barrier. Curr Opin Nephrol Hypertens 2009; 18: 331-335
34. Menzel S, Moeller MJ: Role of the podocyte in proteinuria. Pediatr Nephrol 2011; 26: 1775-1780
35. Skoberne A, Konieczny A, Schiffer M: Glomerular epithelial cells in the urine: What has to be done to make them worthwhile?. Am J Phisiol Renal Physiol 2009; 296:F230-F241
36. Garovic VD, Wagner SJ, Petrovic LM, et al: Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007; 22: 1136-1143
37. Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
38. Sugimoto H, Hamano Y, Charytan D, et al: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt- 1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608
39. Sison K, Eremina V, Baelde H, et al: Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010; 21: 1691-1701
40. Hayman SR, Leung N, Grande JP, Garovic VD: VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012; 14: 285-294
41. Lanctot L, Naranjo CA: Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 1995; 58: 692-698
42. Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients. A meta-Analysis. JAMA 2011; 305: 487-494
43. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011; 104: 599-604
44. Garovic VD, Craici IM, Wagner SJ, et al: Mass spectrometry as a novel method for detection of podocyturia in preeclampsia. Nephrol Dial Transplant 2013; 28: 1555-1561
45. Craici IM, Wagner SJ, Bailey KR, et al: Podocyturia predates proteinuria and clinical features of preeclampsia - longitudinal prospective study. Hypertension 2013; 61: 1289-1296.